Synthetic drugs for the treatment of vitiligo: a patent review (2010–2015)

References

• Sampogna F, Raskovic D, Guerra L, et al. Identification of categories at risk for high quality of life impairment in patients with vitiligo. Br J Dermatol. 2008 Aug;159(2):351–359.
   PubMed Web of Science ®Google Scholar
• Parsad D, Dogra S, Kanwar AJ. Quality of life in patients with vitiligo. Health Qual Life Outcomes. 2003 Oct 23;1:58.
   PubMedGoogle Scholar
• Dwivedi M, Laddha NC, Shajil EM, et al. The ACE gene I/D polymorphism is not associated with generalized vitiligo susceptibility in Gujarat population. Pigment Cell Melanoma Res. 2008 Jun;21(3):407–408.
   PubMed Web of Science ®Google Scholar
• Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 2007 May–Jun;73(3):149–156.
   PubMed Web of Science ®Google Scholar
• Singh M, Singh G, Kanwar AJ, et al. Clinical pattern of vitiligo in Libya. Int J Dermatol. 1985 May;24(4):233–235.
   PubMed Web of Science ®Google Scholar
• Alikhan A, Felsten LM, Daly M, et al. Vitiligo: a comprehensive overview part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011 Sep;65(3):473–491.
   PubMed Web of Science ®Google Scholar
• Das SK, Majumder PP, Chakraborty R, et al. Studies on vitiligo. I. Epidemiological profi le in Calcutta, India. Genet Epidemiol. 1985;2(1):71–78.
   PubMedGoogle Scholar
• Ezzedine K, Diallo A, Léauté-Labrèze C, et al. Pre- vs. post-pubertal onset of vitiligo: multivariate analysis indicates atopic diathesis association in pre-pubertal onset vitiligo. Br J Dermatol. 2012 Sep;167(3):490–495.
   PubMed Web of Science ®Google Scholar
• Forschner T, Buchholtz S, Stockfleth E. Current state of vitiligo therapy-evidence-based analysis of the literature. J Dtsch Dermatol Ges. 2007 Jun;5(6):467–475.
   PubMedGoogle Scholar
• Laberge G, Mailloux CM, Gowan K, et al. Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Res. 2005 Aug;18(4):300–305.
   PubMedGoogle Scholar
• Zettinig G, Tanew A, Fischer G, et al. Autoimmune diseases in vitiligo: do anti-nuclear antibodies decrease thyroid volume? Clin Exp Immunol. 2003 Feb;131(2):347–354.
   PubMed Web of Science ®Google Scholar
• Marinho FDS, Cirino PV, Fernandes NC. Clinical epidemiological profile of vitiligo in children and adolescents. An Bras Dermatol. 2013;88(6):1026–1028.
   PubMed Web of Science ®Google Scholar
• Guerra L, Dellambra E, Brescia S, et al. Vitiligo: pathogenetic hypotheses and targets for current therapies. Curr Drug Metab. 2010 Jun 1;11(5):451–467.
   PubMed Web of Science ®Google Scholar
• Silverberg NB. Update on childhood vitiligo. Curr Opin Pediatr. 2010 Aug;22(4):445–452.
   PubMed Web of Science ®Google Scholar
• Hann SK, Lee HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol. 1996;35:671–674.
   PubMed Web of Science ®Google Scholar
• Brazzelli V, Antoninetti M, Palazzini S, et al. Critical evaluation of the variants influencing the clinical response of vitiligo: study of 60 cases treated with ultraviolet B narrow-band phototherapy. J Eur Acad Dermatol Venereol. 2007 Nov;21(10):1369–1374.
   PubMed Web of Science ®Google Scholar
• Taieb A, Alomar A, Böhm M, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013 Jan;168(1):5–19.
   PubMed Web of Science ®Google Scholar
• Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol. 1997 Dec;133(12):1525–1528.
   PubMed Web of Science ®Google Scholar
• Singh A, Kanwar AJ, Parsad D, et al. Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris. Indian J Dermatol Venereol Leprol. 2014 Jan–Feb;80(1):29–35.
   PubMed Web of Science ®Google Scholar
• Slominski A, Tobin DJ, Shibahara S, et al. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004;84(4):1155–1228.
   PubMed Web of Science ®Google Scholar
• Eves PC, MacNeila S, Haycock JW. α -Melanocyte stimulating hormone, inflammation and human melanoma. Peptides. 2006;27:444–452.
   PubMed Web of Science ®Google Scholar
• Chhajlani V, Wikberg JES. Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA. FEBS Lett. 1992;309:417–420.
   PubMed Web of Science ®Google Scholar
• Mountjoy KG, Robbins LS, Mortrud MT, et al. The cloning of a family of genes that encode the melanocortin receptors. Science. 1992;257:1248–1251.
   PubMed Web of Science ®Google Scholar
• Mountjoy KG. The human melanocyte stimulating hormone receptor has evolved to become “super-sensitive” to melanocortin peptides. Mol Cell Endocrinol. 1994;102:R7–R11.
   PubMed Web of Science ®Google Scholar
• Philippe W; Clinuvel Pharmaceuticals ltd. Α-MSH analogues for treating or preventing vitiligo. NZ2588183. 2012.
   Google Scholar
• Philippe W; Clinuvel Pharmaceuticals ltd. Therapy for vitiligo. US20110130705. 2011.
   Google Scholar
• Martel P, Suzuki I, Voegel J, et al.; Galderma Research & Development. Combination of a prostaglandin receptor agonist and an MC1R receptor agonist for the treatment and/or prevention of pigmentation disorders. US20140371147. 2014.
   Google Scholar
• Thomas BMA, Cassidy PJ; Mimetica Pty Ltd. Methods of modulating the activity of the MC1 receptor and treatment of conditions related to this receptor. US20140128380. 2014.
   Google Scholar
• Abdel-Malek ZA, Koikov L, Knittel JJ; University of Cincinnati. Pharmaceutical compositions and therapeutic methods of use comprising selective agonists of melanocortin 1 receptor. WO2014081846. 2014.
   Google Scholar
• Puri N, van der Weel MB, de Wit FS, et al. Basic fibroblast growth factor promotes melanin synthesis by melanocytes. Arch Dermatol Res. 1996;288:633–635.
   PubMed Web of Science ®Google Scholar
• Ramaiah A Pigmentary agent. United States patent no: 6143723. 2000.
   Google Scholar
• Riley PA. Hydroxyanisole depigmentation: in-vivo studies. J Pathol. 1969;97:185–191.
   PubMed Web of Science ®Google Scholar
• Lerner AB, McGuire JS. Melanocyte-stimulating hormone and adrenocorticotrophic hormone. Their relation to pigmentation. N Engl J Med. 1964;270:539–546.
   PubMed Web of Science ®Google Scholar
• Geschwind II, Huseby RA, Nishioka R. The effect of melanocytestimulatinghormone on coat color in the mouse. Recent Prog Horm Res. 1972;28:91–130.
   PubMedGoogle Scholar
• Kauser S, Thody AJ, Schallreuter KU, et al. A fully functional proopiomelanocortin/melanocortin-1 receptor system regulates the differentiation of human scalp hair follicle melanocytes. Endocrinology. 2005;146:532–543.
   PubMed Web of Science ®Google Scholar
• Spencer JD, Gibbons NCJ, Rokos H, et al. Oxidative stress via hydrogen peroxide affects proopiomelanocortin peptides directly in the epidermis of patients with vitiligo. J Invest Dermatol. 2007;127(2):411–420.
   PubMed Web of Science ®Google Scholar
• Chakraborty AK, Orlow SJ, Bolognia JL, et al. Structural/functional relationships between internal and external MSH receptors: modulation of expression in Cloudman melanoma cells by UVB radiation. J Cell Physiol. 1991;147:1–6.
   PubMed Web of Science ®Google Scholar
• Irina AK, Korsunskaya IM, Nartsissov YR. Composition of amino acids for sublingual applying for enhanced skin integument repigmentation in vitiligo and method of its administration. US20110251279. 2011.
   Google Scholar
• Markus B; Universitaetsklinikum Muenster. Compositions for reducing oxidative stress and uses thereof. US20130252903. 2013.
   Google Scholar
• Caroline LPI, Nieland JD, Holtet TL; Anaphore, Inc. HSP70-based treatment for autoimmune diseases and cancer. US20110028403. 2011.
   Google Scholar
• Ramaiah A. Method of reduction of wrinkles on skin or acceleration of wound healing by applying peptides related to basic fibroblast growth factor (bFGF). US20100323962. 2010.
   Google Scholar
• Matteo B, Matteo B. Mia (melanoma inhibitory activity) inhibitors for detecting, preventing and curing vitiligo. WO2012127352. 2012.
   Google Scholar
• Le Poole IC, Guevara-Patino JA, Zloza A; Loyola University Chicago, ZLOZA, Andrew. Mutant HSP70i to prevent autoimmune disease. US20140341935. 2014.
   Google Scholar
• Hantash Basil M, Abu UA; Escape therapeutics, Inc. Peptide tyrosinase activators. US20150152139. 2015.
   Google Scholar
• Jones RM, Buzard D, Schrader T et al. Modulators of the sphingosine-1-phosphate (S1P) receptor useful for the treatment of disorders related thereto. US2010001803. 2010.
   Google Scholar
• Tamaki K, Kikuchi K, Komine M, et al. Therapeutic agent for vitiligo and method of accelerating pigmentation. US20100222275. 2010.
   Google Scholar
• Pincelli C. Nerve growth factor and keratinocytes: a role in psoriasis. Eur J Dermatol. 2000;10(2):85–90.
   PubMed Web of Science ®Google Scholar
• El-Samad ZA, et al. Egypt J Derm Androl. 2006;27(3,4).
   Google Scholar
• Zepeda L, Hector M. Method for extracting, testing and counting dialysed leukocyte extract from shark spleen in order to obtain an enhanced transfer factor, specifically designed to be used as a treatment against the disease known as vitiligo. WO2013039374. 2013.
   Google Scholar
• Magilavy D, Gardner G. Treatment for vitiligo. WO2014043257. 2014.
   Google Scholar
• Siadak Anthony W, Rene Shirley A IL-31 monoclonal antibodies. US20150037331. 2015.
   Google Scholar
• Rajeev J, Sundarraja VK, Tarun N, et al. Topical composition for the treatment of vitiligo. WO2012131734. 2012.
   Google Scholar
• Salafia A, Salafia E. Anti- vitiligo composition. WO2013024487. 2013.
   Google Scholar
• Banerji S, Sem S. Topical pigmentory composition. WO2015049694. 2015.
   Google Scholar
• Jing S, Sha L, Yu J, et al. Application of fluoxetine to treatment of depigmentation diseases. US 20150065580. 2015.
   Google Scholar
• Silverberg NB. Pediatric vitiligo. Pediatr Clin North Am. 2014;61(2):347–366.
   PubMed Web of Science ®Google Scholar
• Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol. 2004 Jul;51(1):52–61.
   PubMed Web of Science ®Google Scholar
• Kanwar AJ, Dogra S, Parsad D. Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol. 2004 Nov;29(6):589–592.
   PubMed Web of Science ®Google Scholar
• Esfandiarpour I, Farajzadeh S. Clinical characteristics of late-onset vitiligo in an Iranian population. Dermatologica Sin. 2012 Jun;30(2):43–46.
   Web of Science ®Google Scholar
• Gopal KV, Rama Rao GR, Kumar YH, et al. Vitiligo: a part of a systemic autoimmune process. Indian J Dermatol Venereol Leprol. 2007 May–Jun;73(3):162–165.
   PubMed Web of Science ®Google Scholar
• Sehgal VN, Srivastava G. Vitiligo: auto-immunity and immune responses. Int J Dermatol. 2006 May;45(5):583–590.
   PubMed Web of Science ®Google Scholar
• Kurtev A, Dourmishev AL. Thyroid function and autoimmunity in children and adolescents with vitiligo. J Eur Acad Dermatol Venereol. 2004 Jan;18(1):109–111.
   PubMed Web of Science ®Google Scholar
• Vitiligo and stem cells: narrowband UVB phototherapy in nonsegmental vitiligo. Available from: https://www.youtube.com/watch?v=4qwCVHBnxR4
   Google Scholar
• Mosenson JA, Flood K, Klarquist J, et al. Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress. Pig Cell and Mel. 2014;27:209–220.
   PubMed Web of Science ®Google Scholar
• Mosenson JA, Zloza A, Nieland JD, et al. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med. 2013;5(174):174ra28. doi:10.1126/scitranslmed.3005127.
   PubMed Web of Science ®Google Scholar
• Jones Robert M, Buzard Daniel J, Kawasaki Andrew M, et al. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders. US20130184307. 2013.
   Google Scholar
• Liotta S, Banchetti M. Topical preparation containing ngf for inducing skin pigmentation and for the treatment of cutaneous dyschromias and vitiligo. WO2013065078. 2013.
   Google Scholar